Therapeutic antibodies targeting CSF1 impede macrophage recruitment in a xenograft model of tenosynovial giant cell tumor

Sarcoma

Volumn 2010, Issue , 2010, Pages

  Nielsen, Torsten O ^a,b   Cheng, Hongwei ^a   Clarkson, Paul W ^b   Gao, Dongxia ^a   Pacheco, Marina ^a   Wang, Yuzhuo ^b  

^a UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^b BRITISH COLUMBIA CANCER AGENCY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CD163 ANTIGEN; COLONY STIMULATING FACTOR 1; COLONY STIMULATING FACTOR 1 MONOCLONAL ANTIBODY 5H4; IMATINIB; MONOCLONAL ANTIBODY; UNCLASSIFIED DRUG;

ADULT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; CHRONIC DRUG ADMINISTRATION; CLINICAL ARTICLE; DRUG EFFICACY; DRUG MECHANISM; DRUG TARGETING; EXPERIMENTAL MODEL; GENE TRANSLOCATION; GIANT CELL TUMOR; HUMAN; HUMAN TISSUE; KIDNEY CAPSULE; MACROPHAGE; MOUSE; NONHUMAN; NONOBESE DIABETIC MOUSE; PATHOPHYSIOLOGY; PIGMENTED VILLONODULAR SYNOVITIS; PRIORITY JOURNAL; SCID MOUSE; TENDON SHEATH; TUMOR XENOGRAFT; XENOTRANSPLANTATION;

EID: 78349259697     PISSN: 1357714X     EISSN: 13691643     Source Type: Journal    
DOI: 10.1155/2010/174528     Document Type: Article

References (26)

1. Sharma V., Cheng E. Y., Outcomes after excision of pigmented villonodular synovitis of the knee Clinical Orthopaedics and Related Research 2009 467 11 2852 2858
2. Layfield L. J., Meloni-Ehrig A., Liu K., Shepard R., Harrelson J. M., Malignant giant cell tumor of synovium (malignant pigmented villonodular synovitis): a histopathologic and fluorescence in situ hybridization analysis of 2 cases with review of the literature Archives of Pathology and Laboratory Medicine 2000 124 11 1636 1641
3. West R. B., Rubin B. P., Miller M. A., Subramanian S., Kaygusuz G., Montgomery K., Zhu S., Marinelli R. J., De Luca A., Downs-Kelly E., Goldblum J. R., Corless C. L., Brown P. O., Gilks C. B., Nielsen T. O., Huntsman D., Van De Rijn M., A landscape effect in tenosynovial giant-cell tumor from activation of CSF1 expression by a translocation in a minority of tumor cells Proceedings of the National Academy of Sciences of the United States of America 2006 103 3 690 695
4. Cupp J. S., Miller M. A., Montgomery K. D., Nielsen T. O., O'Connell J. X., Huntsman D., Rijn M. V. D., Gilks C. B., West R. B., Translocation and expression of CSF1 in pigmented villonodular synovitis, tenosynovial giant cell tumor, rheumatoid arthritis and other reactive synovitides American Journal of Surgical Pathology 2007 31 6 970 976
5. Blay J.-Y., El Sayadi H., Thiesse P., Garret J., Ray-Coquard I., Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT) Annals of Oncology 2008 19 4 821 822
6. Siveen K. S., Kuttan G., Role of macrophages in tumour progression Immunology Letters 2009 123 2 97 102
7. Paulus P., Stanley E. R., Schfer R., Abraham D., Aharinejad S., Colony-stimulating factor-1 antibody reverses chemoresistance in human MCF-7 breast cancer xenografts Cancer Research 2006 66 8 4349 4356
8. Aharinejad S., Paulus P., Sioud M., Hofmann M., Zins K., Schfer R., Stanley E. R., Abraham D., Colony-stimulating factor-1 blockade by antisense oligonucleotides and small interfering RNAs suppresses growth of human mammary tumor xenografts in mice Cancer Research 2004 64 15 5378 5384
9. Dewar A. L., Cambareri A. C., Zannettino A. C. W., Miller B. L., Doherty K. V., Hughes T. P., Bruce Lyons A., Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinib Blood 2005 105 8 3127 3132
10. Wang Y., Revelo M. P., Sudilovsky D., Cao M., Chen W. G., Goetz L., Xue H., Sadar M., Shappell S. B., Cunha G. R., Hayward S. W., Development and characterization of efficient xenograft models for benign and malignant human prostate tissue Prostate 2005 64 2 149 159
11. Cutz J.-C., Guan J., Bayani J., Yoshimoto M., Xue H., Sutcliffe M., English J., Flint J., LeRiche J., Yee J., Squire J. A., Gout P. W., Lam S., Wang Y.-Z., Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes Clinical Cancer Research 2006 12 13 4043 4054
12. Zimmerman D. L., Harrowe G., Cheng L., Methods for preventing and treating cancer metastasis and bone loss associated with cancer metastasis. European patent number: EP1572106(B1), European Patent Office, Assignee: Novartis Vaccines and Diagnostics, Inc., Belgium, 2010
13. Efron B., Better bootstrap confidence intervals Journal of the American Statistical Association 1987 82 397 171 185
14. Hiraga T., Nakamura H., Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals International Journal of Cancer 2009 124 1 215 222
15. Kerkel R., Grazette L., Yacobi R., Iliescu C., Patten R., Beahm C., Walters B., Shevtsov S., Pesant S., Clubb F. J., Rosenzweig A., Salomon R. N., Van Etten R. A., Alroy J., Durand J.-B., Force T., Cardiotoxicity of the cancer therapeutic agent imatinib mesylate Nature Medicine 2006 12 8 908 916
16. Fichtner I., Rolff J., Soong R., Hoffmann J., Hammer S., Sommer A., Becker M., Merk J., Establishment of patient-derived non-small cell lung cancer xenografts as models for the identification of predictive biomarkers Clinical Cancer Research 2008 14 20 6456 6468
17. Richardsen E., Uglehus R. D., Due J., Busch C., Busund L.-T. R., The prognostic impact of M-CSF, CSF-1 receptor, CD68 and CD3 in prostatic carcinoma Histopathology 2008 53 1 30 38
18. Espinosa I., Beck A. H., Lee C.-H., Zhu S., Montgomery K. D., Marinelli R. J., Ganjoo K. N., Nielsen T. O., Gilks C. B., West R. B., Van De Rijn M., Coordinate expression of colony-stimulating factor-1 and colony-stimulating factor-1-related proteins is associated with poor prognosis in gynecological and nongynecological leiomyosarcoma American Journal of Pathology 2009 174 6 2347 2356
19. Sweet M. J., Hume D. A., CSF-1 as a regulator of macrophage activation and immune responses Archivum Immunologiae et Therapiae Experimentalis 2003 51 3 169 177
20. Kawamura K., Komohara Y., Takaishi K., Katabuchi H., Takeya M., Detection of M2 macrophages and colony-stimulating factor 1expression in serous and mucinous ovarian epithelial tumors Pathology International 2009 59 5 300 305
21. Leek R. D., Landers R. J., Harris A. L., Lewis C. E., Necrosis correlates with high vascular density and focal macrophage infiltration in invasive carcinoma of the breast British Journal of Cancer 1999 79 5-6 991 995
22. Lissbrant I. F., Stattin P., Wikstrom P., Damber J. E., Egevad L., Bergh A., Tumor associated macrophages in human prostate cancer: relation to clinicopathological variables and survival International Journal of Oncology 2000 17 3 445 451
23. Lee C.-H., Espinosa I., Vrijaldenhoven S., Subramanian S., Montgomery K. D., Zhu S., Marinelli R. J., Peterse J. L., Poulin N., Nielsen T. O., West R. B., Gilks C. B., Van De Rijn M., Prognostic significance of macrophage infiltration in leiomyosarcomas Clinical Cancer Research 2008 14 5 1423 1430
24. Al-Sarireh B., Eremin O., Tumour-associated macrophages (TAMS): disordered function, immune suppression and progressive tumour growth Journal of the Royal College of Surgeons of Edinburgh 2000 45 1 1 16
25. Brownlow N., Russell A. E., Saravanapavan H., Wiesmann M., Murray J. M., Manley P. W., Dibb N. J., Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis Leukemia 2008 22 3 649 652
26. Taylor J. R., Brownlow N., Domin J., Dibb N. J., FMS receptor for M-CSF (CSF-1) is sensitive to the kinase inhibitor imatinib and mutation of Asp-802 to Val confers resistance Oncogene 2006 25 1 147 151